华兰生物(002007) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥867,612,696.57, representing a 10.20% increase compared to ¥787,309,418.97 in the same period last year[5] - Net profit attributable to shareholders was ¥313,135,984.76, up 19.62% from ¥261,773,937.60 year-on-year[5] - The net profit excluding non-recurring gains and losses increased by 35.35%, amounting to ¥299,741,568.52 compared to ¥221,458,779.28 in the previous year[5] - Total operating profit increased to ¥397,453,634.36, up from ¥331,130,131.08, representing a growth of approximately 19.98% year-over-year[19] - Net profit attributable to the parent company reached ¥313,135,984.76, compared to ¥261,773,937.60 in the previous period, marking an increase of about 19.58%[20] - Basic earnings per share rose to ¥0.1715 from ¥0.1431, reflecting a growth of approximately 19.88%[20] - The company’s total profit amounted to ¥384,573,318.12, compared to ¥328,375,091.95 in the previous period, showing an increase of approximately 17.14%[19] Cash Flow - The net cash flow from operating activities decreased significantly by 71.75%, totaling ¥14,178,581.71, down from ¥50,186,473.40 in the same period last year[5] - Cash flow from operating activities generated a net cash inflow of ¥14,178,581.71, down from ¥50,186,473.40, indicating a decline of about 71.73%[22] - Cash flow from investing activities resulted in a net outflow of ¥356,667,079.56, compared to a smaller outflow of ¥64,142,690.50 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥16,638,920,951.35, reflecting a 2.02% increase from ¥16,309,951,355.29 at the end of the previous year[5] - Current assets totaled ¥10,549,823,747.89, up from ¥9,616,191,068.19 at the beginning of the period, reflecting a growth of about 9.7%[15] - Total liabilities amounted to ¥2,466,351,246.39, slightly up from ¥2,463,225,371.87, showing a marginal increase[16] - Total assets reached ¥16,638,920,951.35, compared to ¥16,309,951,355.29 at the beginning of the period, reflecting an increase of about 2.0%[16] - The equity attributable to the parent company increased to ¥12,172,136,621.05 from ¥11,858,784,465.45, a growth of approximately 2.6%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 146,328[11] - The largest shareholder, Ankang, holds 17.92% of the shares, amounting to 327,787,406 shares[11] - The company has not reported any significant changes in the top 10 shareholders or their participation in margin trading activities[12] Expenses - The company reported a significant increase in financial expenses by 112.69%, primarily due to a decrease in interest income[9] - Total operating costs increased to ¥553,612,323.28 from ¥544,582,536.78, reflecting a rise of about 1.89%[19] - Research and development expenses were ¥66,459,646.88, down from ¥72,713,577.15, indicating a decrease of approximately 8.66%[19] - The company reported investment income of ¥38,443,296.73, an increase from ¥34,260,128.01, representing a growth of about 6.38%[19] Cash and Receivables - Cash and cash equivalents decreased to ¥1,102,190,831.95 from ¥1,366,659,508.49, a decline of approximately 19.4%[14] - Trade receivables increased to ¥1,870,813,379.20 from ¥1,798,428,848.41, representing a growth of about 4.0%[15] - Inventory rose to ¥2,231,831,545.80 from ¥2,028,565,707.69, indicating an increase of approximately 10.0%[15] - Cash and cash equivalents at the end of the period decreased to ¥1,096,939,137.47 from ¥1,168,607,650.23, a decline of approximately 6.13%[23]